What is ZyVersa Therapeutics Inc's earnings per share (EPS)?

ZyVersa Therapeutics Inc (ZVSA) reported diluted earnings per share of $-4.18 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ZyVersa Therapeutics Inc Financials

ZVSA

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows ZyVersa Therapeutics Inc (ZVSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZVSA FY2025 2026-05-13

Recent filings show a cash-dependent development model where external financing rather than operating inflows keeps the business moving.

From FY2022 through FY2024, reported losses and operating cash burn stayed aligned: net loss was -$14.0M in FY2022 and -$9.4M in FY2024, while operating cash flow remained negative each year. Because financing inflows added about $13.7M across that span as operations consumed cash, the balance sheet was supplying the fuel rather than accounting adjustments masking a self-funding business.

By FY2025, liquidity had become extremely thin, with cash of $102K against current liabilities of $12.7M. Since current assets were only $348K and also represented essentially all total assets, there was little asset depth available to cushion near-term obligations.

The capital structure also moved from positive equity to a deficit: equity shifted from $99.7M in FY2022 to -$12.4M in FY2025. With shares outstanding rising sharply over the same period, funding came from new claims on the business rather than from retained earnings or cash generated inside the operation.

Financial Health Signals

Financial health score pending refresh

We are recalculating ZyVersa Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-4.18

ZyVersa Therapeutics Inc earned $-4.18 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$102K

YoY-93.4%

ZyVersa Therapeutics Inc held $102K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

ZyVersa Therapeutics Inc had 8M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$1.1M

YoY-37.4%

ZyVersa Therapeutics Inc invested $1.1M in research and development in fiscal year 2025. This represents a decrease of 37.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ZVSA Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$1.1M-37.4%	$1.8M-44.5%	$3.2M-40.7%	$5.4M
SG&A Expenses	N/A	$7.4M-34.4%	$11.2M+47.4%	$7.6M
Operating Income	N/A	-$9.1M+91.5%	-$107.8M-728.0%	-$13.0M
Interest Expense	-$513K-90.2%	-$270K-59149.5%	$457+100.1%	-$428K
Income Tax	-$852K-12726.5%	$7K+100.1%	-$9.5M	N/A
Net Income	N/A	-$9.4M+90.4%	-$98.3M-599.7%	-$14.0M
EPS (Diluted)	$-4.18	$-8.48	$-1089.70-109970.7%	$-0.99

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$58K	N/A	$365K-10.9%	$410K+58.4%	$259K	N/A	$436K-38.5%	$709K
SG&A Expenses	$1.2M	N/A	$1.7M+6.4%	$1.6M-13.3%	$1.9M	N/A	$1.8M-10.3%	$2.0M
Operating Income	-$1.3M	N/A	N/A	-$2.0M+4.7%	-$2.1M	N/A	-$2.3M+17.6%	-$2.8M
Interest Expense	-$133K	N/A	-$131K-1.0%	-$130K-8.8%	-$120K	N/A	-$132K-226856.9%	-$58
Income Tax	N/A	N/A	-$852K	N/A	N/A	N/A	N/A	$10K
Net Income	-$1.8M	N/A	N/A	-$2.2M+2.0%	-$2.3M	N/A	-$2.4M+13.1%	-$2.8M
EPS (Diluted)	$-0.22	N/A	$-2.56-456.5%	$-0.46	$-0.73	N/A	$-2.43+26.6%	$-3.31

ZVSA Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$463K-97.8%	$20.6M-6.9%	$22.1M-81.3%	$118.5M
Current Assets	$463K-73.0%	$1.7M-48.8%	$3.4M-47.3%	$6.4M
Cash & Equivalents	$102K-93.4%	$1.5M-51.2%	$3.1M-46.8%	$5.9M
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$11.9M
Total Liabilities	$12.9M+6.4%	$12.1M+9.5%	$11.0M-40.4%	$18.5M
Current Liabilities	$12.9M+14.4%	$11.2M+10.2%	$10.2M+24.5%	$8.2M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	-$12.4M-245.4%	$8.5M-23.1%	$11.1M-88.9%	$99.7M
Retained Earnings	-$137.6M-22.2%	-$112.6M-9.1%	-$103.2M-1997.4%	-$4.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$742K+60.2%	$463K-55.4%	$1.0M-94.7%	$19.6M-6.4%	$21.0M+1.9%	$20.6M+6.1%	$19.4M-0.2%	$19.5M
Current Assets	$742K+60.2%	$463K-53.4%	$996K+81.3%	$549K-74.0%	$2.1M+23.0%	$1.7M+339.5%	$390K-39.1%	$641K
Cash & Equivalents	$303K+197.4%	$102K-80.7%	$528K+632.4%	$72K-95.5%	$1.6M+5.3%	$1.5M+1145.5%	$123K+2.9%	$119K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.9M+15.7%	$12.9M+0.7%	$12.8M-5.7%	$13.5M+5.3%	$12.9M+6.4%	$12.1M-2.5%	$12.4M+14.3%	$10.8M
Current Liabilities	$14.9M+15.7%	$12.9M+0.7%	$12.8M+0.6%	$12.7M+5.7%	$12.0M+6.9%	$11.2M-2.7%	$11.5M+15.5%	$10.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$14.1M-14.0%	-$12.4M-5.6%	-$11.7M-292.2%	$6.1M-25.0%	$8.1M-4.5%	$8.5M+21.2%	$7.0M-18.5%	$8.6M
Retained Earnings	-$139.4M-1.3%	-$137.6M-0.5%	-$136.9M-16.9%	-$117.1M-1.9%	-$114.9M-2.0%	-$112.6M-1.3%	-$111.2M-2.2%	-$108.8M

ZVSA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	N/A	-$7.5M+13.8%	-$8.7M-483.5%	-$1.5M
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$5.9M-0.7%	$6.0M+219.3%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$799K-93.2%	-$414K+70.6%	-$1.4M+7.5%	-$1.5M+14.1%	-$1.8M-45.9%	-$1.2M-97.8%	-$614K+67.9%	-$1.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.0M+8093.0%	-$13K-100.7%	$1.9M+10613.6%	-$18K-101.0%	$1.9M-29.4%	$2.6M+324.7%	$618K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ZVSA Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	-110.5%+777.1pp	-887.6%-873.5pp	-14.1%
Return on Assets	N/A	-45.7%+398.8pp	-444.5%-432.7pp	-11.8%
Current Ratio	0.04-0.1	0.15-0.2	0.33-0.4	0.78
Debt-to-Equity	-1.04-2.5	1.42+0.4	1.00+0.8	0.19
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	-36.3%-8.5pp	-27.8%	N/A	-34.2%-2.1pp	-32.1%
Return on Assets	-241.6%	N/A	N/A	-11.3%-0.5pp	-10.8%	N/A	-12.4%+1.8pp	-14.2%
Current Ratio	0.05+0.0	0.04-0.0	0.08+0.0	0.04-0.1	0.18+0.0	0.15+0.1	0.03-0.0	0.06
Debt-to-Equity	-1.05-0.0	-1.04+0.1	-1.09-3.3	2.22+0.6	1.58+0.2	1.42-0.3	1.76+0.5	1.26
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$12.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Purple Biotech Ltd PPBT

$1.5M

Windtree Therapeutics Inc WINT

$13.8M

CDT Equity CDT

$2.0M

Lipella Pharmaceuticals Inc LIPO

$11.8M

Salarius Pharmaceuticals Inc SLRX

$4.9M

Frequently Asked Questions

What are ZyVersa Therapeutics Inc's total assets?

ZyVersa Therapeutics Inc (ZVSA) had $463K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does ZyVersa Therapeutics Inc spend on research and development?

ZyVersa Therapeutics Inc (ZVSA) invested $1.1M in research and development during fiscal year 2025.

How many shares does ZyVersa Therapeutics Inc have outstanding?

ZyVersa Therapeutics Inc (ZVSA) had 8M shares outstanding as of fiscal year 2025.

What is ZyVersa Therapeutics Inc's current ratio?

ZyVersa Therapeutics Inc (ZVSA) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is ZyVersa Therapeutics Inc's debt-to-equity ratio?

ZyVersa Therapeutics Inc (ZVSA) had a debt-to-equity ratio of -1.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is ZyVersa Therapeutics Inc's debt-to-equity ratio negative or unusual?

ZyVersa Therapeutics Inc (ZVSA) has negative shareholder equity of -$12.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.